Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 14;12(3):e0173089.
doi: 10.1371/journal.pone.0173089. eCollection 2017.

Tamoxifen use and acute pancreatitis: A population-based cohort study

Fan-Gen Hsu  1   2 , Yow-Wen Hsieh  1   2 , Ming-Jyh Sheu  1 , Che-Chen Lin  3   4 , Cheng-Li Lin  4 , Chung Y Hsu  5 , Chang-Yin Lee  6   7 , Mei-Yin Chang  8 , Kuang-Hsi Chang  9
Affiliations

Tamoxifen use and acute pancreatitis: A population-based cohort study

Fan-Gen Hsu et al. PLoS One. .

Abstract

Background: Several case reports have indicated that tamoxifen induced acute pancreatitis (AP); but no pharmacoepidemiological data support the claim. Therefore, we investigated whether tamoxifen use is correlated with the risk of AP in patients with breast cancer.

Methods: This population-based cohort study used the Taiwan National Health Insurance Research Database. A cohort of 22 005 patients aged ≥20 years with breast cancer from January 1, 2000 to December 31, 2009 was identified and the date of cancer diagnosis was set as the index date. The end point was developing AP during the follow-up. Hazard ratios (HRs) and 95% confidence intervals (CIs) were evaluated to determine the correlation between the risk of AP and tamoxifen use. Because the drug use varied over time, it was measured as a time-dependent covariate in the Cox proportional hazard model. The same approaches were applied in PS-matched cohorts.

Results: After adjustment for covariates and medication use including fluorouracil and doxorubicin, the risk of AP was not significant between tamoxifen users and tamoxifen nonusers (adjusted HR = 0.94, 95% CI = 0.74-1.19) in the non-matching cohorts. The results revealed no dose-response trend between tamoxifen use and the risk of AP (adjusted HR = 0.98, 95% CI = 0.96-1.00). The comorbidities DM and gallstones were associated with a significantly increased risk of AP. Similar trends were observed in PS-matched cohorts.

Conclusions: No significant correlation was observed between tamoxifen use and the risk of AP in patients with breast cancer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. March 2015;65(2):87–108. 10.3322/caac.21262 - DOI - PubMed
    1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. November 26 1998;339(22):1609–1618. 10.1056/NEJM199811263392207 - DOI - PubMed
    1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. May 14–20 2005;365(9472):1687–1717. 10.1016/S0140-6736(05)66544-0 - DOI - PubMed
    1. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. January 2015;16(1):67–75. 10.1016/S1470-2045(14)71171-4 - DOI - PMC - PubMed
    1. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev. April 2009;35(2):175–184. 10.1016/j.ctrv.2008.09.007 - DOI - PubMed